国立病院機構北海道がんセンターは、札幌市白石区にある病院。北海道内唯一の「都道府県がん診療連携拠点病院」に指定されており、札幌市内のみならず北海道全域をカバーしている。施設の老朽化・狭隘化や診療機能強化のため、現在地にて全面建替工事を行い、2020年11月完成。

During the past decade, Nho Hokkaido Cancer Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Nho Hokkaido Cancer Center" are "Diffuse Large B-cell Lymphoma" (1 trials), "Lymphoma" (1 trials) and "Non Hodgkins Lymphoma" (1 trials). Many other conditions were trialed in "Nho Hokkaido Cancer Center" in a lesser frequency.

Most popular intervention types in "Nho Hokkaido Cancer Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "parsaclisib" (2 trials), "R-CHOP" (1 trials), "lenalidomide" (1 trials) and "tafasitamab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nho Hokkaido Cancer Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Nho Hokkaido Cancer Center". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Nho Hokkaido Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nho Hokkaido Cancer Center, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".